VIDEO: Latanoprost implant for glaucoma shows improved IOP at 48 weeks
CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Michael Coote, MB, BS, FRANZCO, GAICD, of Melbourne Eye Specialists, presents positive safety and efficacy data for PA5108, an ocular implant for the treatment of glaucoma.
The phase 2 clinical trial investigated PA5108 (latanoprost, PolyActiva) for 48 weeks, during which it showed statistically significant improvements in IOP that were determined to be equivalent to topical latanoprost.
According to Coote, PA5108 has “succeeded in what it is required to do and will continue to be looked at in an over 12-month study.”
Collapse
Waddell V. PolyActiva. AAO 2024 glaucoma/digital showcase. Presented at: Eyecelerator@AAO; Oct. 17, 2024; Chicago.
Read more about